Spruce Biosciences (SPRB) Operating Income (2019 - 2026)
Spruce Biosciences (SPRB) posted quarterly Operating Income of -$12.0 million for Q1 2026, up 17.29% year-over-year from -$10.2 million in Q1 2025, and down 7.99% quarter-over-quarter from -$11.1 million in Q4 2025.
Spruce Biosciences (SPRB) Operating Income (2019 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Operating Income for 8 consecutive years, with -$12.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income rose 17.29% year-over-year to -$12.0 million; the TTM figure through Mar 2026 stood at -$34.0 million (up 41.38% YoY), while the FY2025 annual figure was -$36.5 million, up 34.97% from the prior year.
- Operating Income eased to -$12.0 million in Q1 2026 per SPRB's latest filing, from -$11.1 million in the prior quarter.
- Across five years, Operating Income topped out at -$2.7 million in Q2 2025 and bottomed at -$24.1 million in Q4 2024.
- Historically, Operating Income has averaged -$12.0 million across 5 years, with a median of -$11.9 million in 2022.
- Annual changes were most pronounced in 2024 — Operating Income tumbled 115.64% — and 2025, when it soared 73.18%.
- Spruce Biosciences' Operating Income stood at -$12.1 million in 2022, then rose by 7.81% to -$11.2 million in 2023, then sank by 115.64% to -$24.1 million in 2024, then soared by 53.89% to -$11.1 million in 2025, then dropped by 7.99% to -$12.0 million in 2026.
- Business Quant data shows SPRB's Operating Income at -$12.0 million in Q1 2026, -$11.1 million in Q4 2025, and -$8.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Spruce Biosciences | 127.07 Mn | 127.07 Mn | - | -16.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.51 Mn |
| Mar 31, 2026 | -11.99 Mn |
| Dec 31, 2025 | -11.10 Mn |
| Sep 30, 2025 | -8.23 Mn |
| Jun 30, 2025 | -2.69 Mn |
| Mar 31, 2025 | -14.49 Mn |
| Dec 31, 2024 | -24.07 Mn |
| Sep 30, 2024 | -9.41 Mn |
| Jun 30, 2024 | -10.04 Mn |
| Mar 31, 2024 | -12.63 Mn |
| Dec 31, 2023 | -11.16 Mn |
| Sep 30, 2023 | -13.66 Mn |
| Jun 30, 2023 | -13.97 Mn |
| Mar 31, 2023 | -13.20 Mn |
| Dec 31, 2022 | -12.11 Mn |
| Sep 30, 2022 | -11.56 Mn |
| Jun 30, 2022 | -11.88 Mn |
| Mar 31, 2022 | -11.73 Mn |
| Dec 31, 2021 | -9.14 Mn |
| Sep 30, 2021 | -11.40 Mn |